These are top 10 stocks traded on the Robinhood UK platform in July
HINGHAM, Mass. - Microbot Medical Inc. (NASDAQ:MBOT), a developer of the LIBERTY Endovascular Robotic System, is actively preparing for the system’s anticipated U.S. launch projected for the third quarter of 2025. The company, currently valued at $102 million, has seen its stock surge 178% over the past six months. According to InvestingPro analysis, the company appears fairly valued at current levels. The company announced today the addition of Michael Lytle as the head of Sales Operations & Analytics to bolster its commercial team ahead of the launch.
The LIBERTY System, a single-use, fully disposable endovascular robotic system, is currently under review by the U.S. Food and Drug Administration (FDA). An updated decision from the FDA on Microbot’s 510(k) submission is expected within the original scheduled review window, and the company remains confident that the decision will not impact the planned launch timeline. InvestingPro data shows the company maintains a strong financial position with more cash than debt and ample liquidity to meet short-term obligations.
Harel Gadot, Chairman, CEO & President of Microbot Medical, expressed optimism about the recent interactions with the FDA and the company’s readiness for the upcoming launch. "We continue to operate with full momentum and position the company for an anticipated launch during the third quarter of this year," said Gadot.
Michael Lytle’s prior experience at ZOLL Cardiac Management Solutions is expected to enhance Microbot’s market intelligence tools and optimize the sales cycle. "We believe that Michael’s addition will strengthen our launch readiness plans, and that his expertise will help us target the right markets, allocate resources effectively, and accelerate commercial execution," Gadot concluded.
It is important to note that the LIBERTY System is not yet available for sale in the U.S., and FDA clearance is not guaranteed. The information in this article is based on a press release statement from Microbot Medical Inc. Analysts maintain a bullish outlook with a $9 price target, though InvestingPro subscribers can access 8 additional key insights about MBOT’s financial health and market position.
In other recent news, Microbot Medical has been slated for inclusion in the Russell Microcap Index, as announced by FTSE Russell. This development is part of the annual reconstitution of Russell indexes, which will be effective from June 30, 2025. Additionally, Microbot Medical is preparing for a decision from the U.S. Food and Drug Administration regarding the market clearance of its LIBERTY Endovascular Robotic System, expected in the second quarter of 2025. The company has strengthened its leadership team by appointing new senior officers, including Allison Rosefort as Vice President of Marketing and Lisa Dobbins as Director of Human Resources.
In governance updates, Microbot Medical has amended its by-laws to lower the quorum requirement for shareholder meetings to one-third of the votes, down from a majority. The company has also filed a Preliminary Proxy Statement with the SEC for its annual stockholders’ meeting on June 10, 2025, after a previously planned special meeting was canceled due to a lack of quorum. Meanwhile, H.C. Wainwright has maintained a Buy rating on Microbot Medical, with a price target of $9, following positive results from the ACCESS-PVI pivotal trial of the LIBERTY system. The trial showed a 100% success rate in robotic navigation and a significant reduction in radiation exposure for operators.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.